These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32453265)

  • 21. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 25. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
    Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
    Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.
    Rodríguez-Nóvoa S; Cuenca L; Morello J; Córdoba M; Blanco F; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2010 Aug; 65(8):1567-9. PubMed ID: 20534626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.
    Zubiaur P; Saiz-Rodríguez M; Villapalos-García G; Navares-Gómez M; Koller D; Abad-Santos F
    Pharmacogenet Genomics; 2021 Apr; 31(3):53-59. PubMed ID: 33044391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
    Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
    Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
    Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
    Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.